CIK 0001228627 · Non-accelerated filer<br>Smaller reporting company
Opus Genetics, Inc.
Sign in to watch- Ticker
- IRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 113516358
- Phone
- (984) 884-6030
- Business address
- 8 DAVIS DRIVE, SUITE 220, DURHAM, NC, 27713
- Former names
- Ocuphire Pharma, Inc., REXAHN PHARMACEUTICALS, INC., CORPORATE ROAD SHOW DOT COM INC, FERRARO FRANK
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,211,769
- in 7 filings, $50K under 10b5-1 plans
Net −$3,211,769. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Foundation Fighting Blindness Retinal Degeneration Fund −$2.8M Director sold 15% of stake
- Gagnon Robert E. −$177K Chief Financial Officer sold 7% of stake
- Magrath George −$145K Chief Executive Officer sold 2% of stake
- YERXA BENJAMIN R −$117K President sold 5% of stake
- SCHACHLE JOSEPH K −$17K Chief Operating Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-22 | Jayagopal Ashwath Chief Scientific & Dev. Ofc. | Grant or award | +400,000 | 525,807 | ||
| 2026-01-22 | Gagnon Robert E. Chief Financial Officer | Grant or award | +400,000 | 600,000 | ||
| 2026-01-18 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | Shares withheld for taxes | −3,390 | $2.10 | $7K | 106,628 |
| 2026-01-10 | Zaremba Rabourn Amy Head of Fin. Quality Assurance | Shares withheld for taxes | −3,950 | $1.93 | $8K | 110,018 |
| 2026-01-06 | Gallagher Cam Director | Grant or award | +67,000 | 1,991,430 | ||
| 2026-01-01 | MANUSO JAMES S J Director | Grant or award | +31,188 | 292,951 | ||
| 2026-01-01 | Graves Adrienne L Director | Grant or award | +23,643 | 103,147 | ||
| 2026-01-01 | Bennett Jean Director | Grant or award | +21,127 | 234,652 | ||
| 2026-01-01 | Ainsworth Sean Director | Grant or award | +42,507 | 297,325 | ||
| 2025-12-31 | Gallagher Cam Director | Grant or award | +33,000 | 1,924,430 | ||
| 2025-12-29 | Gallagher Cam Director | Purchase | +81,000 | $1.98 | $160K | 1,891,430 |
| 2025-12-29 | Gallagher Cam Director | Purchase | +83,000 | $1.97 | $163K | 83,000 |
| 2025-12-09 | Foundation Fighting Blindness Retinal Degeneration Fund Director | Sale | −4,000,000 | $2.15 | $8.6M | 5,492,171 |
| 2025-11-01 | Magrath George Chief Executive Officer | Shares withheld for taxes | −30,350 | $2.30 | $70K | 1,291,654 |
| 2025-11-01 | Magrath George Chief Executive Officer | Shares withheld for taxes | −30,350 | $2.30 | $70K | 1,291,654 |
| 2025-10-22 | YERXA BENJAMIN R President | Shares withheld for taxes | −23,795 | $1.95 | $46K | 319,005 |
| 2025-09-10 | Gagnon Robert E. Chief Financial Officer | Grant or award | +200,000 | 200,000 | ||
| 2025-09-02 | Gagnon Robert E. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2025-08-25 | Gallagher Cam Director | Grant or award | +869,565 | $1.15 | $1000K | 1,810,430 |
| 2025-08-25 | Ainsworth Sean Director | Grant or award | +86,956 | $1.15 | $100K | 254,818 |
Page 3 of 7 · 136 trades